1. Home
  2. DAKT vs ABUS Comparison

DAKT vs ABUS Comparison

Compare DAKT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Daktronics Inc.

DAKT

Daktronics Inc.

N/A

Current Price

$19.74

Market Cap

944.7M

Sector

Industrials

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$4.24

Market Cap

848.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DAKT
ABUS
Founded
1968
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
944.7M
848.8M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
DAKT
ABUS
Price
$19.74
$4.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
236.8K
1.4M
Earning Date
03-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
0.75
0.87
Revenue
$608,932,000.00
$14,083,000.00
Revenue This Year
$12.06
N/A
Revenue Next Year
$9.16
$239.71
P/E Ratio
$25.49
$4.89
Revenue Growth
6.89
128.21
52 Week Low
$13.30
$3.04
52 Week High
$28.27
$5.10

Technical Indicators

Market Signals
Indicator
DAKT
ABUS
Relative Strength Index (RSI) 47.98 43.42
Support Level $18.76 $4.16
Resistance Level $20.40 $4.60
Average True Range (ATR) 0.55 0.19
MACD -0.07 -0.02
Stochastic Oscillator 41.12 23.97

Price Performance

Historical Comparison
DAKT
ABUS

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: